Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine Sulfate |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Clofarabine | Clolar | Clofarex | Clolar (clofarabine) is a purine nucleoside analog that inhibits ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair, and induces apoptosis by inhibiting mitochondrial function (NCI Drug Dictionary). | |
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Dexamethasone | Adexone | Desametasone | ||
Idarubicin | Idamycin | Idarubicin Hcl | Chemotherapy - Anthracycline 13 | Idarubicin is an anthracycline, which inhibits DNA replication thereby preventing RNA and protein synthesis and, in combination with other approved drugs, is FDA approved for acute myelogenous leukemia (FDA.gov). |
Sorafenib | Nexavar | BAY 43-9006 | CSF1R Inhibitor 27 FLT3 Inhibitor 61 KIT Inhibitor 55 PDGFR-beta Inhibitor 14 RAF Inhibitor (Pan) 23 RET Inhibitor 48 VEGFR2 Inhibitor 36 | Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is FDA approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov). |
Vincristine Sulfate | Oncovin | 22-Oxovincaleukoblastine|vincristine | Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02135874 | Phase II | Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Rituximab + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Vincristine Sulfate | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | Recruiting | USA | 0 |